JP2018505169A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018505169A5 JP2018505169A5 JP2017539594A JP2017539594A JP2018505169A5 JP 2018505169 A5 JP2018505169 A5 JP 2018505169A5 JP 2017539594 A JP2017539594 A JP 2017539594A JP 2017539594 A JP2017539594 A JP 2017539594A JP 2018505169 A5 JP2018505169 A5 JP 2018505169A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- compound
- hydrogen
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CCC1CC*(Cc2ccccc2)CC1 Chemical compound CCC1CC*(Cc2ccccc2)CC1 0.000 description 11
- WATASAJREKAPOT-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1OC)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1OC)=O WATASAJREKAPOT-UHFFFAOYSA-N 0.000 description 1
- FFROMNOQCNVNIH-UHFFFAOYSA-N CC(C)CC1CCCCC1 Chemical compound CC(C)CC1CCCCC1 FFROMNOQCNVNIH-UHFFFAOYSA-N 0.000 description 1
- PIAWUDAHTYGVCH-UHFFFAOYSA-N COC(c1ccc(CN2CCC(CNC(C3)C33c4ccccc4CCC3)CC2)cc1)=O Chemical compound COC(c1ccc(CN2CCC(CNC(C3)C33c4ccccc4CCC3)CC2)cc1)=O PIAWUDAHTYGVCH-UHFFFAOYSA-N 0.000 description 1
- MQLFSPBSNWUXSO-UHFFFAOYSA-N ICC1CCOCC1 Chemical compound ICC1CCOCC1 MQLFSPBSNWUXSO-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562110209P | 2015-01-30 | 2015-01-30 | |
| US62/110,209 | 2015-01-30 | ||
| PCT/US2016/015440 WO2016123387A1 (en) | 2015-01-30 | 2016-01-28 | Therapeutic compounds and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018505169A JP2018505169A (ja) | 2018-02-22 |
| JP2018505169A5 true JP2018505169A5 (enExample) | 2019-03-07 |
| JP6636031B2 JP6636031B2 (ja) | 2020-01-29 |
Family
ID=55361970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017539594A Expired - Fee Related JP6636031B2 (ja) | 2015-01-30 | 2016-01-28 | 治療用化合物およびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10301253B2 (enExample) |
| EP (1) | EP3250552B1 (enExample) |
| JP (1) | JP6636031B2 (enExample) |
| CN (1) | CN107438593B (enExample) |
| WO (1) | WO2016123387A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106045862B (zh) * | 2015-04-10 | 2019-04-23 | 上海迪诺医药科技有限公司 | 环丙胺类螺(杂)环化合物、其药物组合物及应用 |
| US10059668B2 (en) | 2015-11-05 | 2018-08-28 | Mirati Therapeutics, Inc. | LSD1 inhibitors |
| SG11201805645QA (en) | 2015-12-29 | 2018-07-30 | Mirati Therapeutics Inc | Lsd1 inhibitors |
| ES3057783T3 (en) | 2016-03-15 | 2026-03-04 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases |
| WO2017158136A1 (en) | 2016-03-16 | 2017-09-21 | Oryzon Genomics, S.A. | Methods to determine kdm1a target engagement and chemoprobes useful therefor |
| MD3532459T2 (ro) | 2016-10-26 | 2024-06-30 | Constellation Pharmaceuticals Inc | Inhibitori ai LSD1 și utilizările medicale ale acestora |
| WO2018083189A1 (en) | 2016-11-03 | 2018-05-11 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
| CN110291089B (zh) | 2017-01-17 | 2022-05-27 | 海帕瑞吉尼克斯股份有限公司 | 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂 |
| CN108530302A (zh) * | 2017-03-06 | 2018-09-14 | 华东师范大学 | 2`,3`-二氢螺[环丙烷-1,1`-茚]-2-胺衍生物及其制备方法和应用 |
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| SI3661510T1 (sl) | 2017-08-03 | 2025-03-31 | Oryzon Genomics, S.A. | Postopki zdravljenja vedenjskih sprememb |
| NZ766447A (en) | 2018-01-31 | 2021-12-24 | Mirati Therapeutics Inc | Prc2 inhibitors |
| WO2020152280A1 (en) * | 2019-01-24 | 2020-07-30 | Fundación Pública Andaluza Progreso Y Salud | Lsd1 inhibitors for use in the treatment of type 2 diabetes |
| WO2020157069A1 (en) * | 2019-01-28 | 2020-08-06 | NodThera Limited | Amino heterocyclic compounds and uses thereof |
| US20220151999A1 (en) | 2019-03-20 | 2022-05-19 | Oryzon Genomics, S.A. | Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat |
| US20220151998A1 (en) | 2019-03-20 | 2022-05-19 | Oryzon Genomics, S.A. | Methods of treating borderline personality disorder |
| JP7624404B2 (ja) | 2019-04-22 | 2025-01-30 | ミラティ セラピューティクス，インク． | Ｐｒｃ２阻害剤としてのナフチリジン誘導体 |
| AU2020288563A1 (en) | 2019-06-05 | 2022-01-06 | Mirati Therapeutics, Inc. | Imidazo(1,2-c)pyrimidine derivatives as PRC2 inhibitors for treating cancer |
| CN110256429B (zh) * | 2019-06-17 | 2021-06-22 | 广东药科大学 | 一种具有螺环结构的氨基嘧啶类化合物及其制备方法和应用 |
| JP2022546908A (ja) | 2019-07-05 | 2022-11-10 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Ｋｄｍ１ａ阻害剤を使用した小細胞肺がんの個別化された処置のためのバイオマーカーおよび方法 |
| CA3231846A1 (en) | 2021-04-08 | 2022-10-13 | Tamara Maes | Combinations of lsd1 inhibitors for treating myeloid cancers |
| EP4522136A1 (en) | 2022-05-09 | 2025-03-19 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
| CN119497613A (zh) | 2022-05-09 | 2025-02-21 | 奥莱松基因组股份有限公司 | 使用lsd1抑制剂治疗nf1-突变肿瘤的方法 |
| WO2024110649A1 (en) | 2022-11-24 | 2024-05-30 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors and menin inhibitors for treating cancer |
| WO2025085311A1 (en) * | 2023-10-16 | 2025-04-24 | Board Of Regents, The University Of Texas System | Methods and compositions for the treatment of kmt2d-deficient cancers |
| CN117510444B (zh) * | 2024-01-06 | 2024-03-08 | 成都瑞尔医药科技有限公司 | 一种呋塞米的精制工艺 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| CA2066428C (en) | 1989-09-08 | 2000-11-28 | Bert Vogelstein | Structural alterations of the egf receptor gene in human gliomas |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| DK0659439T3 (da) | 1993-12-24 | 2002-01-14 | Merck Patent Gmbh | Immunkonjugater |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| HU216142B (hu) | 1994-07-21 | 1999-04-28 | Akzo Nobel N.V. | Ciklusos keton-peroxidokat tartalmazó kompozíciók, és azok alkalmazása (ko)polimerek módosítására |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| DE69536015D1 (de) | 1995-03-30 | 2009-12-10 | Pfizer Prod Inc | Chinazolinone Derivate |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| JPH11507535A (ja) | 1995-06-07 | 1999-07-06 | イムクローン システムズ インコーポレイテッド | 腫瘍の成長を抑制する抗体および抗体フラグメント類 |
| EP0836605B1 (en) | 1995-07-06 | 2002-02-06 | Novartis AG | Pyrrolopyrimidines and processes for the preparation thereof |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| JP3370340B2 (ja) | 1996-04-12 | 2003-01-27 | ワーナー―ランバート・コンパニー | チロシンキナーゼの不可逆的阻害剤 |
| DE69716916T2 (de) | 1996-07-13 | 2003-07-03 | Glaxo Group Ltd., Greenford | Kondensierte heterozyklische verbindungen als protein kinase inhibitoren |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| ES2201484T3 (es) | 1997-05-06 | 2004-03-16 | Wyeth Holdings Corporation | Utilizacion de compuestos de quinazolina para el tratamiento de la enfermedad de la poliquistosis renal. |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| NZ503991A (en) | 1997-11-06 | 2001-11-30 | American Cyanamid Co | Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps |
| ES2188254T3 (es) | 1998-11-19 | 2003-06-16 | Warner Lambert Co | N-(4-(3-chloro-4-fluoro-fenilamino)-7-(3-morfolin-4-il-propoxi)-quin azolin-6-il)-acrilamada, un inhibidor irreversible de tirosina quinasas. |
| AU2004312284B2 (en) * | 2004-01-08 | 2010-08-05 | Medivir Ab | Non-nucleotide reverse transcriptase inhibitors |
| WO2010143582A1 (ja) * | 2009-06-11 | 2010-12-16 | 公立大学法人名古屋市立大学 | フェニルシクロプロピルアミン誘導体及びlsd1阻害剤 |
| AU2011244478B2 (en) * | 2010-04-20 | 2014-07-17 | Fondazione IEO-CCM | Tranylcypromine derivatives as inhibitors of histone demethylase LSD1 and/or LSD2 |
| SI2598482T1 (sl) * | 2010-07-29 | 2018-09-28 | Oryzon Genomics, S.A. | Inhibitorji demetilaze lsd1 na osnovi arilciklopropilamina in njihova medicinska uporaba |
| CA2831143C (en) * | 2011-03-25 | 2019-05-21 | Glaxosmithkline Intellectual Property Development Limited | Cyclopropylamines as lsd1 inhibitors |
| UA114406C2 (uk) * | 2011-08-09 | 2017-06-12 | Такеда Фармасьютікал Компані Лімітед | Похідні циклопропанаміну як інгібітори lsd1 |
| CN107266345B (zh) * | 2011-10-20 | 2021-08-17 | 奥瑞泽恩基因组学股份有限公司 | 作为lsd1抑制剂的(杂)芳基环丙胺化合物 |
| CN106045862B (zh) * | 2015-04-10 | 2019-04-23 | 上海迪诺医药科技有限公司 | 环丙胺类螺(杂)环化合物、其药物组合物及应用 |
| WO2017109061A1 (en) * | 2015-12-23 | 2017-06-29 | Ieo - Istituto Europeo Di Oncologia S.R.L. | Spirocyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a |
-
2016
- 2016-01-28 WO PCT/US2016/015440 patent/WO2016123387A1/en not_active Ceased
- 2016-01-28 JP JP2017539594A patent/JP6636031B2/ja not_active Expired - Fee Related
- 2016-01-28 EP EP16704983.2A patent/EP3250552B1/en active Active
- 2016-01-28 CN CN201680019097.8A patent/CN107438593B/zh active Active
-
2017
- 2017-07-24 US US15/658,219 patent/US10301253B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017530984A5 (enExample) | ||
| CO2023007504A2 (es) | Derivados de carboxamida tricíclica como inhibidores de prmt5 | |
| JP6905075B2 (ja) | 腫瘍の治療または予防のための併用療法 | |
| CL2023001738A1 (es) | Inhibidores de prmt5 | |
| RU2316326C2 (ru) | Способ и композиция для лечения ракового заболевания, тозилат и фармацевтически приемлемые соли n-(4-хлор-3-(трифторметил)фенил)-n'-(4-(2-(n-метилкарбамоил)-4-пиридилокси)фенил)мочевины | |
| JP6456383B2 (ja) | イソチオシアネート系化合物と抗癌薬の併用 | |
| JP2018510851A5 (enExample) | ||
| JP2014511383A5 (enExample) | ||
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| RU2014111069A (ru) | Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение | |
| RU2014141362A (ru) | Комбинированная терапия пролиферативных нарушений | |
| RU2014102362A (ru) | Антитромботические соединения | |
| EP3053578B1 (en) | Combination cancer therapy using azabicyclo compound | |
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| RU2013127655A (ru) | Фармацевтическая комбинация паклитаксела и ингибитора cdk | |
| EA201500050A1 (ru) | Бифтордиоксалан-амино-бензимидазольные ингибиторы киназы для лечения рака, аутоиммунного воспаления и нарушений цнс | |
| CA3116731A1 (en) | Combinations for immune-modulation in cancer treatment | |
| CN102438608A (zh) | 包含ave8062和索拉非尼的抗肿瘤组合 | |
| JP2015514796A (ja) | ２から３０ｍｇ／ｋｇの範囲の用量で癌を治療するのに使用するためのデキサナビノールまたはこの誘導体 | |
| ATE401080T1 (de) | (3-((chinazolin-4-yl)amino)-1h-pyrazol-1- yl)acetamid derivate und verwandte verbindungen als aurora kinase inhibitoren zur behandlung von proliferativen erkrankungen wie krebs | |
| RU2018107930A (ru) | Агонисты tlr4, их композиции и применение для лечения рака | |
| JP2019513812A (ja) | 化学療法の改善 | |
| RU2013148627A (ru) | Производные тиено [2, 3-d] пиримидина и их применение для лечения аритмии | |
| JP2018502100A5 (enExample) |